Polygenic Embryo Screening: Where Do We Stand? – ESHRE
European Society of Human Reproduction and Embryology (ESHRE) shared a post on LinkedIn:
“Polygenic Embryo Screening: Where Do We Stand?
Polygenic embryo screening (PES) can now assess IVF embryos for risks of heart disease, diabetes, schizophrenia and cancers. It’s already available, but highly controversial.
The disconnect: patients show strong interest – healthcare professionals have serious concerns.
Join this ESHRE webinar as international experts share new research on these diverging attitudes. Through focused presentations and panel discussion, we’ll explore:
- What drives patient demand vs. professional hesitation
- How views differ across cultures and demographics
- The implications for policy, education and patient care
Be part of shaping how we navigate this emerging frontier in hashtag#ReproductiveGenetics.
Date: 10 February 2026 | 17:00 CET
Find out more.”
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
Oct 11, 2025, 06:44The Global IVF Market Is Set to Reach $65B by 2032 – Meddilink
-
Jan 9, 2026, 11:20Lucile Ferreux: What History Teaches Us About the Place of Human Health
-
Jan 9, 2026, 11:02January Insights Reflecting on 2025’s Top Fertility Research – RBMO
-
Jan 8, 2026, 19:00Michaela Hofbauer: 2025 Marked a Turning Point for Women’s Health
-
Jan 8, 2026, 18:55Margot Lherbet: Insights on Surrogacy Perspectives from French Experts
-
Jan 8, 2026, 18:52Meghan White: Exploring Endometriosis Impact on Male Partners
-
Jan 8, 2026, 18:47Transforming Endometriosis Diagnosis Through Symptom Tracking – Womb WatchAI
-
Jan 8, 2026, 18:43Anushree Nandan: Cutting-Edge Research on PRC1 Proteins and Endometriosis
-
Jan 8, 2026, 17:46Swapna Nhavi: Revolutionizing Ovarian Tissue Preservation
-
Jan 8, 2026, 12:24Sun-Wei Guo Joins Foraviset’s Scientific Advisory Board – Foraviset
